FDA's plan for cell and tissue-based products

WASHINGTON - The FDA announced on Friday a plan for "reinventing" the regulation of products derived from cells and tissues.

The proposed regulatory framework addresses a wide variety of therapies, including somatic cell therapy, the use of blood from the placenta and umbilical cord, and processed structural

Read the full 462 word article

How to gain access

Continue reading with a
two-week free trial.